Market Currents
More on Amgen (AMGN) / Micromet (MITI) deal: The acquisition provides Amgen with blinatumomab, a...
-
Thursday, January 26, 2012, 8:20 AM ETMore on Amgen (AMGN) / Micromet (MITI) deal: The acquisition provides Amgen with blinatumomab, a leukemia treatment in Phase 2 trials. The offer of $11/share is a 33% premium to Micromet's close yesterday. (PR)
Other date
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles
